Moderna Set to Join S&P 500 PR Newswire NEW YORK, July 15, 2021 NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the...
– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as...
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Honeywell International Inc. (Nasdaq: HON), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX...
By Adria Calatayud AstraZeneca PLC said Wednesday that its $39 billion acquisition of Alexion Pharmaceuticals Inc. is expected to close next week after it obtained final clearance from the U.K...
By Adria Calatayud The U.K. Competition and Markets Authority said Wednesday that it won't refer AstraZeneca PLC's anticipated acquisition of Alexion Pharmaceuticals Inc. for further...
- Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2...
– With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH – – Approval based on interim results from Phase 3 study showing...
By Mark Maurer AstraZeneca PLC appointed an Alexion Pharmaceuticals Inc. executive as its new finance chief as the Covid-19 vaccine maker works to complete the acquisition of the company. The...
By Adria Calatayud AstraZeneca PLC said Friday that it has appointed Aradhana Sarin, currently executive vice-president and chief financial officer of Alexion Pharmaceuticals Inc., as its next...
By Anthony O. Goriainoff AstraZeneca PLC said Thursday that it has priced 800 million euros ($975.6 million) of fixed-rate notes with a coupon of 0.375%. The funds will be used toward the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.